144 related articles for article (PubMed ID: 20151846)
1. Fulvestrant: a unique antiendocrine agent for estrogen-sensitive breast cancer.
Kabos P; Borges VF
Expert Opin Pharmacother; 2010 Apr; 11(5):807-16. PubMed ID: 20151846
[TBL] [Abstract][Full Text] [Related]
2. Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer.
Oakman C; Moretti E; Santarpia L; Di Leo A
Future Oncol; 2011 Feb; 7(2):173-86. PubMed ID: 21345137
[TBL] [Abstract][Full Text] [Related]
3. Emerging data on the efficacy and safety of fulvestrant, a unique antiestrogen therapy for advanced breast cancer.
Scott SM; Brown M; Come SE
Expert Opin Drug Saf; 2011 Sep; 10(5):819-26. PubMed ID: 21699443
[TBL] [Abstract][Full Text] [Related]
4. Hormonal therapy for breast cancer: focus on fulvestrant.
Versea L; Rosenzweig M
Clin J Oncol Nurs; 2003; 7(3):307-11. PubMed ID: 12793337
[TBL] [Abstract][Full Text] [Related]
5. Nursing perspectives on fulvestrant for the treatment of postmenopausal women with metastatic breast cancer.
Litsas G
Clin J Oncol Nurs; 2011 Dec; 15(6):674-81. PubMed ID: 22119979
[TBL] [Abstract][Full Text] [Related]
6. Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme.
Mlineritsch B; Psenak O; Mayer P; Moik M; Namberger K; Hauser-Kronberger C; Greil R
Breast Cancer Res Treat; 2007 Nov; 106(1):105-12. PubMed ID: 17295045
[TBL] [Abstract][Full Text] [Related]
7. Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients.
Poggio F; Lambertini M; Blondeaux E; Vaglica M; Levaggi A; Pronzato P; Del Mastro L
Expert Rev Clin Pharmacol; 2016 Sep; 9(9):1153-61. PubMed ID: 27545815
[TBL] [Abstract][Full Text] [Related]
8. Fulvestrant--a novel estrogen receptor antagonist for the treatment of advanced breast cancer.
Buzdar AU
Drugs Today (Barc); 2008 Sep; 44(9):679-92. PubMed ID: 19137123
[TBL] [Abstract][Full Text] [Related]
9. Hormone therapy for breast cancer, with an emphasis on the pure antiestrogen fulvestrant: mode of action, antitumor efficacy and effects on bone health.
Journé F; Body JJ; Leclercq G; Laurent G
Expert Opin Drug Saf; 2008 May; 7(3):241-58. PubMed ID: 18462183
[TBL] [Abstract][Full Text] [Related]
10. Role of fulvestrant in the management of postmenopausal breast cancer.
Krell J; Januszewski A; Yan K; Palmieri C
Expert Rev Anticancer Ther; 2011 Nov; 11(11):1641-52. PubMed ID: 22050013
[TBL] [Abstract][Full Text] [Related]
11. Fulvestrant in heavily pretreated metastatic breast cancer: is it still effective as a very advanced line of treatment?
Safra T; Greenberg J; Ron IG; Ben-Yosef R; Inbar M; Sarid D; Yaal-Hahoshen N
Isr Med Assoc J; 2008 May; 10(5):339-43. PubMed ID: 18605354
[TBL] [Abstract][Full Text] [Related]
12. Fulvestrant antiestrogen for treatment of breast cancer.
Hancock CM
Clin J Oncol Nurs; 2003; 7(2):201-2. PubMed ID: 12696217
[TBL] [Abstract][Full Text] [Related]
13. Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer.
Bartsch R; Bago-Horvath Z; Berghoff A; DeVries C; Pluschnig U; Dubsky P; Rudas M; Mader RM; Rottenfusser A; Fitzal F; Gnant M; Zielinski CC; Steger GG
Eur J Cancer; 2012 Sep; 48(13):1932-8. PubMed ID: 22459763
[TBL] [Abstract][Full Text] [Related]
14. Fulvestrant: pharmacologic profile versus existing endocrine agents for the treatment of breast cancer.
Buzdar AU; Robertson JF
Ann Pharmacother; 2006 Sep; 40(9):1572-83. PubMed ID: 16912252
[TBL] [Abstract][Full Text] [Related]
15. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032.
Ingle JN; Suman VJ; Rowland KM; Mirchandani D; Bernath AM; Camoriano JK; Fishkin PA; Nikcevich DA; Perez EA;
J Clin Oncol; 2006 Mar; 24(7):1052-6. PubMed ID: 16505423
[TBL] [Abstract][Full Text] [Related]
16. Fulvestrant ('Faslodex'): current and future role in breast cancer management.
Howell A
Crit Rev Oncol Hematol; 2006 Mar; 57(3):265-73. PubMed ID: 16473018
[TBL] [Abstract][Full Text] [Related]
17. Fulvestrant in postmenopausal women with advanced breast cancer.
Bross PF; Baird A; Chen G; Jee JM; Lostritto RT; Morse DE; Rosario LA; Williams GM; Yang P; Rahman A; Williams G; Pazdur R
Clin Cancer Res; 2003 Oct; 9(12):4309-17. PubMed ID: 14555500
[TBL] [Abstract][Full Text] [Related]
18. The future of fulvestrant ("Faslodex").
Howell A
Cancer Treat Rev; 2005; 31 Suppl 2():S26-33. PubMed ID: 16198056
[TBL] [Abstract][Full Text] [Related]
19. Clinical development of fulvestrant ("Faslodex").
Howell A; Abram P
Cancer Treat Rev; 2005; 31 Suppl 2():S3-9. PubMed ID: 16198055
[TBL] [Abstract][Full Text] [Related]
20. The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer.
Ciruelos E; Pascual T; Arroyo Vozmediano ML; Blanco M; Manso L; Parrilla L; Muñoz C; Vega E; Calderón MJ; Sancho B; Cortes-Funes H
Breast; 2014 Jun; 23(3):201-8. PubMed ID: 24589524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
